Early CEO Cyriac Roeding raises $44M for genetic constructs that force cancer cells to reveal and destroy themselves

Well, okay. So, there there's I was going to I I thought we had our friends over at NFM Live. They will be coming on in just a few minutes, but we will be joined by Sarak or Sak Siraak. Sriak. Good to meet you. Thank you for joining the stream.

Uh why don't you kick us off with an introduction on yourself and the company? All right. Well, uh I am Syriak from Early. Early is an early cancer treatment company. And essentially what we do is we uh create genetic constructs that are injected into your body and they disperse everywhere in your body.

They enter healthy cells randomly and if you happen to have cancer cells, they will also enter those. But only if it's cancer, these genetic constructs will switch on like a light switch. And then they turn the cancer cells into little factories that are forced to make any protein of choice.

In other words, you can make something that makes the cancer visible or you can make something that activates your immune system to attack and kill the cancer. Mhm.

So the whole thing is is relevant because in the last 50 years we've always tried to find some markers on cancer cells that make them detectable or druggable. Right. Billions of dollars have gone into that. And yet we still have 600,000. Yeah.

We still have 600,000 uh people dying from cancer in the US every year and 10 million globally. So something needs to change. What's the background of the company? Is this a tech transfer? This come out of an academic lab? Uh what is your background? Yeah, I'm actually not a biologist.

I out of 35 people, I'm like one of two or three people who don't have that background. I'm an engineer. I'm a serial entrepreneur. And the idea came out of Stanford University and it was one of the world's top people in early cancer detection who then himself sadly passed away from cancer. Wow.

including his own son died at 16 from cancer and his wife died two years after him. The whole family is wiped out. So I met him. Was that out of curiosity? Was that environmental exposure or No, no, no. It's mostly genetic genetic.

Uh and the the mother had a genetic uh genetic mutation that then got transferred to the sun. M uh and what Sam Gambia died from, the inventor of the whole thing is unclear to this point. It was a cancer of unknown origin. You didn't even know where the primary tumor came from.

So, a big a very tragic story, but he was committed to flipping the tables against cancer. So I don't know if you guys have Jordi uh or John whether you have anybody in your family or in in your friends uh circle that has been affected by cancer. Yeah. Yeah. Of course.

You know it's just kind of crazy that we are always behind a step behind or two steps behind. We're always trying to find the next marker that we could hook on to. Mhm. So what if we could stop looking for any marker altogether? Mhm.

What if instead we could force the cancer to reveal itself and make its own therapy to kill itself? So what's the pathway to commercialization? Uh I imagine you have to go through FDA approvals at some point. Yeah, we have to go through a phase one, two, three trial. Sure. Uh and then to commercialization.

And we have spent uh the last seven years cracking this really hard problem. You know what the biggest problem is in cancer? What's a cancer cell and what's not a cancer cell? Yeah. Of course. Because because you know different from a virus, this is your own cell that has changed just a little bit. Mhm.

And so differentiating that from a normal cell or from something that looks like cancer but is totally benign is really hard. And that's what we've spent so much time and energy on with AI.

We're we're essentially producing AI results, liquefy them, put them into the body into a cancer drug that then forces the cancer to produce their own its own therapy against itself. And what's the latest news with the company? Well, we just raised $44 million. Congratulations. [Applause] Not cheap work you're doing.

Sounds expensive. Yeah, biotech is not cheap. So, you know, I don't know if how much you know about the biotech world. It is in the biggest funding crash in the last 20 years on both the public side, the private side.

I know that the the government funding is certainly uh at an all-time low, but across everything actually you named them. It the private funding Yes. is extremely low because of two reasons.

high interest rates which immediately affect a long running product like bio takes 10 to 12 years right and then uh AI is like a vacuum cleaner for money that makes sense it sucks up all the money that goes to tech firms because for VC companies many of them believe they can make a faster return by putting it into AI classic tech of course but bio and and AI is a great interface that is now coming to fruition and then The pharma companies they are concerned about tariffs they are concerned about u China catching up to the US and they start buying ideas and drugs there and then the government is not stepping in to flatten out the curve and you know here I would actually say we really got to make a national commitment to biotech to flatten out this funding curve because you know at the end of the day would you like to be dependent on China providing the most developed life-saving drugs for cancer, for autoimmune diseases.

Do we really want to depend on that? I mean, it's good if they supply them, but what if they don't one day? So, we should actually have a national commitment to biotech to make it uh to to retain the world leadership that the US has had for the last 50 years. Yeah, good point. Uh well, thank you so much for stopping by.

Have a great rest week and uh have a great weekend and congratulations. We'll talk to you soon. Thank you. Talk soon. Byebye. Cheers. We have some major guests in the reream waiting room. Let me tell you about Wander first. Wander. Find your happy place. Find your happy place.